Literature DB >> 30131600

Pembrolizumab: patient selection or immune intensification?

Ravi A Madan1, James L Gulley2.   

Abstract

Entities:  

Year:  2018        PMID: 30131600      PMCID: PMC8232373          DOI: 10.1038/s41585-018-0076-z

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  6 in total

1.  Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.

Authors:  Douglas G McNeel; Jens C Eickhoff; Ellen Wargowski; Christopher Zahm; Mary Jane Staab; Jane Straus; Glenn Liu
Journal:  Oncotarget       Date:  2018-05-22

2.  Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Authors:  Karim Boudadi; Daniel L Suzman; Valsamo Anagnostou; Wei Fu; Brandon Luber; Hao Wang; Noushin Niknafs; James R White; John L Silberstein; Rana Sullivan; Donna Dowling; Rana Harb; Thomas R Nirschl; Brendan A Veeneman; Scott A Tomlins; Yipeng Wang; Adam Jendrisak; Ryon P Graf; Ryan Dittamore; Michael A Carducci; Mario A Eisenberger; Michael C Haffner; Alan K Meeker; James R Eshleman; Jun Luo; Victor E Velculescu; Charles G Drake; Emmanuel S Antonarakis
Journal:  Oncotarget       Date:  2018-06-19

3.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

4.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Authors:  Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cell       Date:  2018-06-14       Impact factor: 41.582

Review 5.  Perspectives on the clinical development of immunotherapy in prostate cancer.

Authors:  Lisa M Cordes; James L Gulley; Ravi A Madan
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285

Review 6.  Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Authors:  Michael M Boyiadzis; John M Kirkwood; John L Marshall; Colin C Pritchard; Nilofer S Azad; James L Gulley
Journal:  J Immunother Cancer       Date:  2018-05-14       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.